Dyne Launches With $50m For Antibody Conjugates That Deliver Oligonucleotides To Muscles
Executive Summary
The start-up incubated by Atlas Venture is focused on the delivery of nucleic acids and other molecules to skeletal, cardiac and smooth muscles. The Series A round will allow Dyne to take its lead program for myotonic dystrophy type 1 (DM1) into the clinic.
You may also be interested in...
Venture Funding Deals: CNS Plays Are Attracting Investment
Polyneuron, Synerkine, Harmony, EIP Pharma and AITI Life Sciences all raised cash in recent weeks to tackle various conditions involving the nervous system. More recent venture funding deals...
Life after Merck: What Idenix's Renaud did next
In June, Merck & Co announced it was bolstering its position in the highly competitive hepatitis C arena with the acquisition of Idenix Pharmaceuticals for $3.85bn (scripintelligence.com, 9 June 2014). The transaction closed in August.
Finance Watch: Pfizer Adds $3.5bn To Cash Stockpile, Reduces Stake In Haleon
Public Company Edition: Pfizer’s stake in Haleon dropped from 32% to 22.6% with a massive sale of shares of the GSK consumer health spinout. Also, Galderma prices its Swiss IPO, Madrigal grosses $600m in a post-approval offering and bluebird secured up to $175m in debt.